Mirati Therapeutics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported revenue was USD 71.79 million compared to USD 11.42 million a year ago. Net loss was USD 80.05 million compared to USD 87.34 million a year ago. Basic loss per share from continuing operations was USD 1.55 compared to USD 1.96 a year ago. For the nine months, revenue was USD 71.79 million compared to USD 11.69 million a year ago. Net loss was USD 382.16 million compared to USD 256.85 million a year ago. Basic loss per share from continuing operations was USD 7.45 compared to USD 5.87 a year ago.